Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

Despite significant advancements in the treatment of other cancers, pancreatic ductal adenocarcinoma (PDAC) remains one of the world’s deadliest cancers. More than 90% of PDAC patients harbor a Kirsten rat sarcoma (KRAS) gene mutation. Although the clinical potential of anti-KRAS therapies has long...

Full description

Bibliographic Details
Main Authors: Szu-Aun Long, Amber M. Amparo, Grace Goodhart, Syed A. Ahmad, Andrew M. Waters
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-05-01
Series:Frontiers in Oncology
Subjects:
PDAC
KRAS inhibitor
pancreatic cancer
KRAS
KRAS inhibition
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1402128/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1402128/full

Similar Items